肝硬化门静脉高压症发病机制的研究现状

doi:10.16139/j.1007-9610.2021.03.003

摘要/Abstract

中图分类号:

R657.34

罗蒙, 李泓杰, 郑磊. 肝硬化门静脉高压症发病机制的研究现状[J]. 外科理论与实践, 2021, 26(03): 195-198.

LUO Meng, LI Hongjie, ZHENG Lei. Study on pathogenesis of cirrhotic portal hypertension: current status[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 195-198.

参考文献 31

[1]	GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8 URL
[2]	de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis[J]. Clin Liver Dis, 2001, 5(3):645-663. pmid: 11565135
[3]	Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference[J]. Hepatology, 2008, 47(5):1764-1772. doi: 10.1002/hep.22273 pmid: 18435460
[4]	郑磊, 孙隆慈, 罗蒙. 肝硬化患者门静脉压力及静脉曲张评估进展[J]. 肝胆胰外科杂志, 2016, 28(3):255-258.
[5]	罗蒙, 吴志勇. 门静脉压力测定在肝硬化门静脉高压症术式选择中的意义[J]. 外科理论与实践, 2009, 14(1):7-9.
[6]	Lin J Y, Zhang CH, Zheng L, et al. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics(HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study[J]. BMJ Open, 2019, 9(12):e028518. doi: 10.1136/bmjopen-2018-028518 URL
[7]	Benoit JN, Womack WA, Hernandez L, et al. “Forward”and “backward” flow mechanisms of portal hypertension. relative contributions in the rat model of portal vein stenosis[J]. Gastroenterology, 1985, 89(5):1092-1096. pmid: 4043666
[8]	Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl):S121-S130.
[9]	Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol, 2011, 6:425-456. doi: 10.1146/annurev-pathol-011110-130246 pmid: 21073339
[10]	Herath CB, Mak K, Burrell LM, et al. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin Ⅱ and methoxamine via an endothelial nitric oxide-media-ted pathway in cirrhotic rat liver[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(1):99-108.
[11]	Herath CB, Lubel JS, Jia Z, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 297(1):98-106.
[12]	Fernandez M. Molecular pathophysiology of portal hypertension[J]. Hepatology, 2015, 61(4):1406-1415. doi: 10.1002/hep.27343 pmid: 25092403
[13]	Vorobioff JD, Groszmann RJ. Portal hypertension - molecular mechanisms[M]// Muriel P. Liver pathophysio-logy-therapies and antioxidants. United Kingdom: Academic Press, 2017:435-449.
[14]	Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy[J]. Gastroenterology, 2000, 118(6):1261-1265. pmid: 10833501
[15]	Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat[J]. Gastroenterology, 1999, 117(5):1222-1228. pmid: 10535886
[16]	Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis[J]. Hepatology, 2006, 44(1):44-52. doi: 10.1002/hep.21228 URL
[17]	May D, Djonov V, Zamir G, et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations[J]. PLoS One, 2011, 6(7):e21478. doi: 10.1371/journal.pone.0021478 URL
[18]	Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdyna-mic state[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(5):G980-G987.
[19]	Zhu Y, Ni T, Lin J, et al. Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS/NO signaling[J]. Biochimie, 2019, 163:128-136. doi: 10.1016/j.biochi.2019.04.006 URL
[20]	Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis[J]. Gastroenterology, 2013, 145(4):874-884. doi: 10.1053/j.gastro.2013.06.036 URL
[21]	di Pascoli M, Sacerdoti D, Pontisso P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2):92-99. doi: 10.1159/000462974 pmid: 28402977
[22]	Fernaandez M, Garciia-Pagaan JC, Casadevall M, et al. Acute and chronic cyclooxygenase blockage in portal-hyper-tensive rats: influence in nitric oxide biosynthesis[J]. Gastroenterology, 1996, 110(5):1529-1535. doi: 10.1053/gast.1996.v110.pm8613060 URL
[23]	Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis[J]. Hepatology, 2005, 42(3):539-548. pmid: 16108046
[24]	Adeagbo AS, Henzel MK. Calcium-dependent phospholipase A2 mediates the production of endothelium-derived hyperpolarizing factor in perfused rat mesenteric prearteriolar bed[J]. J Vasc Res, 1998, 35(1):27-35. pmid: 9482693
[25]	Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule[J]. Hepatology, 2006, 43(2 Suppl 1):S121-S131.
[26]	Du QH, Han L, Jiang JJ, et al. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats[J]. World J Gastroenterol, 2013, 19(13):2065-2072. doi: 10.3748/wjg.v19.i13.2065 URL
[27]	Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins[J]. Hepatology, 2007, 45(2):495-506. doi: 10.1002/hep.21502 pmid: 17256744
[28]	Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease[J]. J Hepatol, 2009, 50(3):604-620. doi: 10.1016/j.jhep.2008.12.011 URL
[29]	Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocolla-teral circulations in portal hypertensive and cirrhotic rats[J]. Hepatology, 2009, 49(4):1245-1256. doi: 10.1002/hep.22758 pmid: 19137587
[30]	Sumanovski LT, Battegay E, Stumm M, et al. Increased angiogenesis in portal hypertensive rats: role of nitric oxide[J]. Hepatology, 1999, 29(4):1044-1049. pmid: 10094944
[31]	Angermayr B, Fernandez M, Mejias M, et al. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats[J]. Gut, 2007, 56(4):560-564. pmid: 16854998

肝硬化门静脉高压症发病机制的研究现状

Study on pathogenesis of cirrhotic portal hypertension: current status

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴辉，富荣昌，杨晓玉，李现政，王召耀. 三种不同血液粘度模型中分叉血流的数值研究[J]. J Shanghai Jiaotong Univ Sci, 2023, 28(4): 450-.
[2]	宋震, 林广贤, 范飞. 皮瓣血流监测方法的研究进展 [J]. 组织工程与重建外科杂志, 2023, 19(1): 83-.
[3]	Chang Jessica, 陈旭晓, 陈拥军. 脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[4]	毕礼明, 王朝晖. 糖尿病肾病发病机制研究进展[J]. 内科理论与实践, 2023, 18(03): 201-205.
[5]	赵晨薇　马刚　林晓曦. 葡萄酒色斑增厚机制的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 83-.
[6]	张超, 高雪. 继发进展型多发性硬化的临床诊断进展[J]. 诊断学理论与实践, 2022, 21(06): 669-676.
[7]	杨文康, 张俊, 王淑秋, 祥巴央宗, 杨翠萍. 我国云南香格里拉地区104例肝硬化患者的病因及临床特征分析[J]. 诊断学理论与实践, 2022, 21(06): 730-734.
[8]	张梦茵, 陈平, 袁晓琴, 蔡波尔, 吴云林. 内镜下组织黏合剂联合硬化剂注射治疗胃静脉曲张临床研究及随访[J]. 外科理论与实践, 2022, 27(05): 443-447.
[9]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[10]	高晶晶, 高艳虹. 早发2型糖尿病流行病学、临床特征及病因机制的研究进展[J]. 内科理论与实践, 2022, 17(04): 344-348.
[11]	孔秀芳, 姜林娣. 大动脉炎发病机制及诊疗研究进展[J]. 内科理论与实践, 2022, 17(03): 262-266.
[12]	鲁晓岚, 夏巧云. 胆汁淤积性瘙痒发病机制及其治疗研究进展[J]. 内科理论与实践, 2022, 17(01): 43-47.
[13]	周香雪, 黄海威. 肝豆状核变性影像学研究进展[J]. 内科理论与实践, 2021, 16(05): 308-314.
[14]	赵英妹, 聂红明, 张珏, 黄燕. 肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(05): 480-483.
[15]	陈炜, 卜俊峰. 肝功能评估方式及在门静脉高压症围术期的应用[J]. 外科理论与实践, 2021, 26(03): 212-216.